GSK statement on meningitis vaccination in the UK

GSK is delighted to have reached an agreement with the UK's Department of Health that will enable babies in the UK to receive its meningitis B vaccine through the NHS immunisation schedule.

We have moved rapidly to conclude negotiations since we acquired the vaccine from Novartis at the beginning of March.

We believe the agreement we have reached offers fair value for the NHS and allows a reasonable return for GSK to ensure that we can continue to invest in creating new treatments and vaccines.

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.